CardiacConnect is seeking to license CardioDataWare™, the software algorithms inherent in CardioDataPad® for use in third party devices. This can be particularly attractive when these devices already have substantial market penetration and/or there are high barriers to entry. Three areas of specific interest to CardiacConnetc are Cardiac monitors, Anesthesia and sleep apnea Monitors. Other possibilities will also be considered.

Anesthesia and Critical Care Monitor

Anesthetics are among the most dangerous drugs approved for general use in that their margin of safety is small and their dose-effect responses are steep. At increasing doses, anesthetics cause hypnosis, a loss of neural reflexes and a loss of sensation of pain. The measurement of the depth of anesthesia is an inexact observational art based on common sense and experience. CardioDataWare™ provides a proprietary quantitative index derived from the autonomic regulation of cardiac function which is sensitive and is able to document numerically the substantial suppression of autonomic neural tone realized during anesthesia. Presently, characteristic changes in electrical activity in the cortex of the brain, as represented in the EEG, have been quantified and used as an index of hypnosis and depth of anesthesia. However, the use of the EEG as the sole index of anesthetic depth is unreliable. During anesthesia, the monitoring of the electrical activity of the heart, as evident in the ECG, is required so the clinician can maintain the heart rate within the acceptable range as well as provide the necessary intervention to address any abnormalities evident within the ECG. Instantaneous (every 30 seconds) derivation of the degree of autonomic tone imbedded within the ECG by CardioDataWare™ will provide a numerical index that will improve patient management, patient safety and patient care. Autonomic suppression is inherent in anesthesia. Measurements with CardioDataWare™ show that in anesthetized dogs, the autonomic low frequency modulation is only 1/30 th of that in awake dogs, and the high frequency modulation 1/200 th of that when awake. This demonstrates the extremely high sensitivity of CardioDataWare™ . There are 40,000,000 inpatient surgeries in 6000 hospitals and clinics in the United States where the measurement of the degree of autonomic suppression could lead to improved clinical care. Due to the barriers to market entry, we anticipate that the revenues will come from licensing this product to major medical device companies.

Sleep apnea

Only 2,000,000 of the estimated 12, 000,000 to 18,000,000 people with sleep disordered breathing have been diagnosed. There are 2,500 sleep laboratories in the US . Persons with sleep apnea have impaired autonomic function. CardioDataWare™ has application in the diagnosis of obstructive versus central sleep apnea. A version of the device incorporated onto the continuous positive air pressure device used to treat sleep apnea enable home monitoring of the patient and assessment of compliance and therapeutic effectiveness. A version of the device could also be incorporated into a device for self-diagnosis of sleep apnea.

If you are interested in finding out how collaborating with CardiacConnetc could benefit your organization, please contact us at  (760) 744-0036 or by e-mail at ccc@cardiacconnect.com

Copy Right CardiacConnect Corporation. All Rights Reserved